Contenido

REFERENCIAS

---

1. Boss N. En: Diccionario Médico Roche Doyma 1993; p.1866.
   
   
2. Resnick N M. Geriatric medicine. En: Harrison‘s Principles of Internal Medicine. 14th Mc Graw Hill, 1998; p.39.
   
   
3. Resnick N M. Medicina geriátrica. En: Diagnostico clínico y tratamiento. Manual Moderno 1999; p.41.
   
   
4. Fries JF. Aging, natural death and the comprension of morbidity. N Engl J Med 1980;303: 130-135.
   
   
5. Olshansky SJ, Carnes BA, Cassel C. In search of Methuselah: estimating the upper limits to human longevity. Science 1990; 250: 634-640.
   
   
6. Hillis LD. Myocardial ischemia. N Engl J Med 1977; 296: 1034-1093.
   
   
7. National Center For Health Statistics: Utilization of short stay hospitals, United States. Health Stat 1987; 31: 197.
   
   
8. Fuster V, Ross R, Toplo E J. Prevalencia, incidencia y mortalidad de la cardiopatía coronaria. En: Aterosclerosis y enfermedad arterial coronaria. Barcelona: Springer-Verlag Ibérica, S.A, 1997; 15-23.
   
   
9. Lakatta E G, Gerstenbkith G, Weisfeldt M L. The aging heart: Structure, function and disease. Braunwald E, ed. Heart disease.5th ed. W.B. Saunders Company, 1997; 1687-1700.
   
   
10. Elveback L, Lie J T. Continued high incidence of coronary artery disease at autopsy in Olmsted Country. Minnesota, 1950 to 1979. Circulation 1984; 70: 345-349
    
    
11. Friesinger GC, Gravanis ME. Aging and the cardiovascular system. En: Gravanis ME, ed. Health and disease in cardiovascular disorders. St. Louis: Mosby, 1995.
    
    
12. Gerstenblith G, Frederiksen J, Yin FCP, et al. Echocardiographic assessment of a normal adult aging population. Circulation 1977; 56: 273.
    
    
13. Burns TR, Klima M, Teasdale TA, et al. Morphometry of the aging heart. Mod Pathol 1990; 3: 336-342.
    
    
14. Yasue H, Matsuyama K, Okumura K, et al. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment: Possible role of early coronary atherosclerosis. Circulation 1990; 81: 482-490.
    
    
15. Taddei S, Virdis A, Mattei P et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981-1987.
    
    
16. Spirito P, Maron BJ. Influence of aging on Doppler echocardiographic indices of left ventricular diastolic. Br Heart J 1988; 59:672-679.
    
    
17. Brandfonbremer M, Landowne M, Shock MW. Changes in cardiac output with age. Circulation 1955; 12:557-561
    
    
18. Rodehefffer RJ, Gerstenblith G, Becker LC, et al. Exercise cardiac output is maintained with advancing age in healthy human subjects: Cardiac dilatation and increased stroke volume compensate for a diminished heart rate. Circulation 1984; 69:203-213.
    
    
19. Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment for the elderly: The effect of competing risks. Ann Intern Med 1996; 22:9-22.
    
    
20. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
    
    
21. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996; 275: 1571-1576
    
    
22. Dahlof B, Lindholm LH, HanssonL, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
    
    
23. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
    
    
24. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349-1354.
    
    
25. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
    
    
26. Lauer MS, Anderson KM, Kannel WB, et al. The impact of obesity on left ventricular mass and geometry: The Framingham Heart Study. JAMA 1991; 266:231-236.
    
    
27. Devereux RB, Dahlof B, Levy D, et al. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension. The PRESERVE trial. Am J Cardiol 1996; 78:61-65.
    
    
28. LaCroix AZ, Lang J, Scherr P et al. Smoking and mortality among older women and men in three communities. N Engl J Med 1991; 324:1619-1625.
    
    
29. Vlietstra RE, Kronmal RA, Oberman A, et al. Effect of cigarette smoking on survival of patients with angiographically documented coronary artery disease: Report from the CASS registry. JAMA 1986; 255:1023-1027.
    
    
30. Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Participants in the Coronary Artery Surgery Study: Beneficial six year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. N Engl J Med 1988; 319:1365-1369.
    
    
31. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all cause mortality in persons older than 70 years. JAMA 1994; 272:1335-1340.
    
    
32. Rubin SM, Sidney S, Black DM, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 1990; 113:916-920.
    
    
33. Benfante R, Reed D. Is elevated serum cholesterol a risk for coronary heart disease in the elderly? JAMA 1990; 263:393-396.
    
    
34. Castelli WP, Wilson PW, Levy D, et al. Cardiovascular risk factors in the elderly. Am J Cardiol 1989; 63(supp): 12H-19H.
    
    
35. Kronmal RA, Cain KC, Ye SZ, et al. Total serum cholesterol levels and mortality risk as function of age. Arch Intern Med 1993; 153:1065-1073.
    
    
36. American College of Physicians. Guidelines for using cholesterol, high density lipoproteins cholesterol, and triglyceride levels as screening test for preventing coronary heart disease in adults. Ann Intern Med 1996; 124:515-517.
    
    
37. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revised. Ann Intern Med 1996; 124: 518-531.
    
    
38. LaRosa JC, Applegate W, Crouse JR III, et al. Cholesterol lowering in the elderly: Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994; 154:529-539.
    
    
39. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease; The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
    
    
40. Furberg CD, Pitt B, Byington RP, et al. Reduction in coronary events during treatment with pravastatina. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries. Am J Cardiol 1995; 76:60C-63C.
    
    
41. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: Evidence for under treatment in women and the elderly. Arch Intern Med 1996; 156:799-805.
    
    
42. Kannel WB. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study. Am Heart J 1985; 110:1100-1107.
    
    
43. Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995;75:894-903.
    
    
44. Manolio TA, Fuberg CD, Semanski L, et al. Association of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women Circulation 1993; 88:2163-2171.
    
    
45. Grodstein F, Meir JS, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-461.
    
    
46. Stanford JL, Weiss NS, Voight LF, el al. Combined estrogen and progestin hormone replacement in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274:137-142.
    
    
47. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens of heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995; 272:199-208.
    
    
48. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91:999-1005.
    
    
49. Baregoot JC, Helms MJ, Mark DB, et al. Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996; 78:613-617.
    
    
50. Detre KM, Myler RK. Kelsey SF, et al. Baseline characteristics of patients in the National Heart Lung and Blood Institute. Percutaneous Transluminal Coronary Angioplasty Registry. Am J Cardiol 1984; 53:7C- 11C.
    
    
51. Stone GW, Grines CL, Browne KF, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The Primary Angioplasty in Myocardial lnfarction (PAMI) trial. J Am Coll Cardiol 1995; 25:370-377.
    
    
52. Thompson RC, Holmes DR Jr., Gersh BJ, et al. Percutaneous transluminal coronary angioplasty in the elderly: Early and long-term results. J Am Coll Cardiol 1991;17:1245-1250.
    
    
53. Muller DWM. Topol EJ, Ellis SG, et al. Multivessel coronary artery disease: A key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction: Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1991: 121:1042-1049.
    
    
54. Kander NH, O’Neill W. Topol EJ, et al. Long-term follow-up of patients treated with coronary angioplasty for acute myocardial infarction. Am Heart J 1999; 118:229-233.
    
    
55. O’Keefe JH, Sutton MB, McCallister BD, et al. Coronary angioplasty versus bypass surgery in patients >70 years old matched for ventricular function. J Am Coll Cardiol 1994;24: 425-430.
    
    
56. BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335:225.
    
    
57. Thompson RC, Holmes DR Jr, Grill DE, et al. Changing outcome of angioplasty in the elderly. J Am Coll Cardiol 1996; 26:8-14.
    
    
58. Gurwitz JH, Gore JM, Goidberg RI, et al. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 1996; 124:283-291.
    
    
59. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med 1996; 335:1857-1863.
    
    
60. Versaci F, Gaspardone A. Tomai F, et al. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. N Engl J Med 1997; 336:817-822.
    
    
61. LaCroix AZ, Guralnik JM, Curb JD, et al. Chest pain and coronary heart disease mortality among older men and women in three communities. Circulation 1990; 81:437-446.
    
    
62. Deekers JW, Fioretti P, Brower RW, et al. Ineligibility for predischarge exercise testing after myocardial infarction in the elderly: implications for prognosis. Eur Heart J 1984; 5:97-100.
    
    
63. Johnson LW, Lozner EC, Johnsn S, et al. Coronary arteriography 1984-1987: A report of the Registry of the Society for Cardiac Angiography and Interventions. I. Results and complications. Cathet Cardiovasc Diagn 1989; 17:5-10.
    
    
64. Calvin JE, Klein LW, VandenBerg BJ, et al. Risk stratification in unstable angina: Prospective validation of the Braunwald Classification. J Am Coll Cardiol 1995; 273:136-141.
    
    
65. GISSI Avoidable Delay Study Group. Epidemiology of avoidable delay in the care of patients with acute myocardial infarction in Italy: A GISSI-generated study. Arch Interm Med 1995; 155:1481-1488.
    
    
66. Maynard C, Weaver WD, Lambrew C. et al. Factors influencing the time to administration of thrombolytic therapy with recombinant tissue plasminogen activator (data from the National Registry of Myocardial Infarction): Participants in the National Registry of Myocardial Infarction. Am J Cardiol 1995; 76:548-552.
    
    
67. Ottesen MM, Kober L, Jorgensen S, et al. Determinants of delay between symptoms and hospital admission in 5978 patients with acute myocardial infarction: The TRACE Study Group. Eur Heart J 1996; 17:429-437.
    
    
68. Sigurdsson E, Thorgeirsson G. Sigvaldason H, et al. Unrecognized myocardial infarction: Epidemiology, clinical characteristics, and the prognostic role of angina pectoris: The Reykjavik Study. Ann Intern Med 1995; 122:96-102.
    
    
69. Nadelnan J. Fishmen WH, Ooi WL, et al. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study. Am J Cardiol 1990; 66:533-537.
    
    
70. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction: An update on the Framingham study. N Engl J Med 1984; 311:1144-1147.
    
    
71. Solomon CG, Lee TH, Cook EF. et al. Comparison of clinical presentation of acute myocardial infarction in patients older than 65 years of age to younger patients: The multicenter chest pain study experience. Am J Cardiol 1989. 63: 772-776.
    
    
72. Aronow WS. Prevalence of presenting symptoms of recognized acute myocardial infarction and of unrecognized healed myocardial infarction in elderly patients. Am J Cardiol 1987: 60:1182-1188.
    
    
73. Maggioni AP. Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. N Engl J Med 1993; 329:1442-1448.
    
    
74. Goldberg RJ, Gore JM, Gurwitz JH. et al. The impact of age on the incidence and prognosis of initial myocardial infarction: The Worcester Heart Attack Study. Am Heart J 1989;117:543-549
    
    
75. White HD, Barbash GI, Califf RM. et al. Age and outcome with contemporary thrombolytic therapy: Results from the GUSTO-I trial. Circulation 1996; 94:1826-1933.
    
    
76. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30 day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41,021 patients. Circulation 1995; 91:1659-1668.
    
    
77. Fibrinolytic Therapy Trialists´ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343:311-321
    
    
78. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA 1994; 272:859-866.
    
    
79. O’Connor CM, Califf RM, Massey EW, et al. Stroke and acute myocardial infarction in the thrombolytic era: Clinical correlates and long-term prognosis. J Am Coll Cardiol 1990; 16:533-540.
    
    
80. ISIS-2 (Second lnternational Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360.
    
    
81. Gruppo Italiano per lo Studio della Sopravivenza nell’lnfarto Miocardico. GISSI-2: A factorial randomized of alteplase versus streptokinase and heparin versus no heparin among 12.490 patients with acute myocardial infarction. Lancet 1990; 336:65-71.
    
    
82. Third International Study of lnfarct Survival Study Group. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anisteplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339:753-770.
    
    
83. Simoons ML, Maggioni AP, Knatterud G. et al. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet 1993; 342:1523-1528.
    
    
84. Gore JM, Granger CB, Sloan MA, et al. Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO-1 Trial. Circulation 1995; 92:2811-2818.
    
    
85. Montague TJ, lkuta RM, Wong RY, et al. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1989). Am J Cardiol 1991; 68:843-847.
    
    
86. Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction: The MITI Project Group. J Am Coll Cardiol 1991; 18:657-662.
    
    
87. Krumholz HM, Pastenak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327:7-13.
    
    
88. Every NR, Parsons LS, Hlatky M, et al. For the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996; 335: 1253-1260.
    
    
89. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995; 333:565-572.
    
    
90. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993: 328:673-679.
    
    
91. The GUSTO-IIb Angioplasty Substudy Investigators, A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336:1621-1628.
    
    
92. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: Patterns of use and outcomes. Circulation 1995: 92:2841-2847
    
    
93. Krmholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes. Ann Intern Med 1996: 124:292-298.
    
    
94. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327:175-181.
    
    
95. BHAT Study Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247:1707-1714.
    
    
96. Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on timolol after acute myocardial infarction. N Engl J Med 1985; 313:1055-1058.
    
    
97. Rutherford JD, Pieffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction: Results of the survival and ventricular enlargement trial. Circulation 1994; 90:1731-1738.
    
    
98. Gruppo Italiano per lo Studio della Sopravvivenza nell´lnfarto Miocardico. GISSI-3 Effects of lisinopril and transdermal glyceryil trinitrate single and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-1121.
    
    
99. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996; 77:551-556.
    
    
100. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: Time for reevaluation. Circulation 1995; 92:1079-1082.
     
     
101. Boden WE. Anti-ischaemic therapy during the follow-up phase of acute coronary syndrome. Is there a role for calcium channel blockers? Drugs 1996; 52: 20-30.
     
     
102. Califf RM, White HD, Van de Werf F, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial. Circulation 1996; 94:1233-1238.
     
     
103. Volpi A. DeVita C, Franzoni MG. et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: Results of the GISSI-2 data base. Circulation 1993; 98:416-429.
     
     
104. Myers MG, Baigrie RS, Charlat ML, el al. Are routine non-invasive tests useful in prediction of outcome after myocardial infarction in elderly people? Lancet 1993; 342:1069-1072.
     
     
105. Peterson ED, Shaw LJ, Califf RM. Risk stratification after myocardial infarction. Ann Intern Med 1997; 126:561-582.
     
     
106. O’Connor GT, Buring JE. Yusuf S. el al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80:234-244.
     
     
107. Lavie CJ, Milani RV. Effects of cardiac rehabilitation programs on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in a large elderly cohort. Am J Cardiol 1995; 76:177-179.
     
     
108. Ades PA, Waldmann ML. Polk D, et al. Referal patterns and exercise response in the rehabilitation of female coronary patients aged >62 years. Am J Cardiol 1992:1422-1425.
     
     
109. Willianis MA, Maresh CM, Esterbrooks DJ. et al. Early exercise training in patients older than age 65 year compared with that in younger patients after acute myocardial infarction or coronary artery bypass grafting. Am J Cardiol 1985: 55:263-266.
     
     
110. Kitzman DW, Higginbotham MB. Cobb FR, et al. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: Failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991; 17:1065-1072.
     
     
111. Schocken DD, Arrieta MJ, Leaverton PE, el al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Cardiol 1992; 20:301-306.
     
     
112. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986: Evidence for increasing population prevalence. Arch Intern Med 1990; 150:769-773.
     
     
113. Rich MW, Beckham Y, Wittenberg C, el al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333:1190-1195.
     
     
114. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure on asymtomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327:685-691.
     
     
115. Bangdiwala SI, Weiner DH, Bourassa MG, et al. Studies of Left- Ventricular Dysfunction (SOLVD) Registry: Rationale, design, methods and description of baseline characteristics. Am J Cardiol 1992; 70:347-353.
     
     
116. Bourassa MG, Gurne 0, Bangdiwala SI, el al. Natural history and patterns of current practice in heart failure: The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 1993; 22:14A- 19A.
     
     
117. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994: 271:1276-1280.
     
     
118. Cody RJ, Torre S, Clark M, el al. Age-related hemodynamic, renal, and hormonal differences among patients with congestive heart failure. Arch Intern Med 1989; 149:1023-1028.
     
     
119. Furberg CD, Psaty BM. Manolio TA, el al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994: 74: 236-241.
     
     
120. Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. European Heart J 1995: 16:741-751.
     
     
121. Ezekowitz MD, Bridgers SL, James KE, el al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affair, Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-1412.
     
     
122. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features, and prognosis of diastolic heart failure: An epidemiological perspective. J Am Coll Cardiol 1995: 26:1565-1574.
     
     
123. Ho KK, Anderson KM. Kannel W, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993: 88: 107-115.
     
     
124. Andersson B, Waagstein F. Spectrum and outcome of congestive heart failure in a hospitalized population. Am Heart J 1997; 126:632-640.
     
     
125. The CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987; 316:1429-1435.
     
     
126. Sallasakul Y, Edwards WD, Naessens JM. et al. Age-related changes in aortic and mitral valve thickness: Implications for two-dimensional echocardiography based on an autopsy study of 200 normal human hearts. Am J Cardiol 1998: 62:424-430.
     
     
127. Otto CM. Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of “degenerative” valvular aortic stenosis: Histological and immunohistochemical studies. Circulation 1994: 90:844-853.
     
     
128. lsoyama S, Wei JY, Izumo S, et al. Effect of age on the development of cardiac hypertrophy produced by aortic constriction in the rat. Circ Res 1987; 61: 337-345.
     
     
129. Murphy ES, Lawson RM, Starr A. el al. Severe aortic stenosis in patients 60 years of age or older: Left ventricular function and 10-years survival after valve replacement. Circulation 1981; 64:II 184-II 188.
     
     
130. Aranki SF. Rizzo RJ. Couper GS, et al. Aortic valve replacement in the elderly: Effect of gender and coronary artery disease on operative mortality. Circulation 1993; 88:17-23.
     
     
131. Freeman WK, Schaff HV. O’Brien PC, et al. Cardiac surgery in the octogenarian: Perioperative outcome and clinical follow-up. J Am Coll Cardiol 1991: 18: 29-35.
     
     
132. Logeais Y, Langanay T, Roussin R, et al. Surgery for aortic stenosis in elderly patients: A study of surgical risk and predictive factors. Circulation 1994: 90:2891-2898.
     
     
133. Elayda MA, Hall RJ, Reut RM, el al. Aortic replacement in patients 80 years and older: Operative risks and long-term results. Circulation 1993; 88: 11-16.
     
     
134. Rioux C, Logeais Y, Leguerrier A. el al. Valvular replacement for aortic stenosis in patients over 70 years: Immediate risk and long-term results (from a consecutive series of 355 patients). Eur Heart J 1988; 9:121-127.
     
     
135. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk evaluating the results of surgery in acquired adult heart disease. Circulation 1989; 79:3-12.
     
     
136. Sprigings DC, Forfar JC. How should we manage symptomatic aortic stenosis in the patient who is 80 or older? Br Heart J 1995; 74:481-484.
     
     
137. Akasaka T, Yoshikaawa J, Yoshida K. et al. Age-related valvular regurgitation: A study by pulsed Doppler echocardiography. Circulation 1987: 76:262-265.
     
     
138. Roman MJ, Devereaux RB, Niles NW, et al. Aortic root dilatation a cause of isolated, severe aortic regurgitation. Prevalence, clinical and echocardiographic patterns, and relation to left ventricular hypertrophy and function. Ann Intern Med 1987; 106:800-807.
     
     
139. Furiquez-Saraf M. Tajik J, Schatt HV, et al. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: Results and clinical implications. J Am Coll Cardiol 1994; 24:1536-1541.
     
     
140. Korn D. DeSanctis RW, Sels S. Massive calcification of the mitral annulus: A clinico-pathological study of 14 cases. N Engl J Med 1962; 267:900-904.
     
     
141. Schoen FJ. Cardiac valve prostheses: Pathological and bioengineering considerations. J Cardiac Surg 1987. 2:65- 108.
     
     
142. Agruss NS, Rosin EY, Adolph RJ. et al. Significance of chronic sinus bradycardia in elderly people. Circulation 1972; 46:924-930.
     
     
143. Gann D, Tolentino A. Samet P. Electrophysiologic evaluation of elderly patients with sinus bradycardia: A long-term follow-up study. Ann Internal Med 1979; 90: 24-29.
     
     
144. Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population: Detection by 24-hour ambulatory electrocardiography. Chest 1982; 81:302-307.
     
     
145. Shiraishi I, Tetsuro T, Minamikawa T, et al. Quantitative histological analysis of the human sinoatrial node during growth and aging. Circulation 1992; 85:2176-2184.
     
     
146. Feinberg WM, Blackshear JL, Laupacis A, Et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995; 155:469-473.
     
     
147. Whittle J, Wickenheiser L, Vanditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997; 157: 441-445.
     
     
148. Epstein LM, Chiesa N, Wong MN, et al. Radiofrequency catheter ablation in the treatment of supraventricular tachycardia in the elderly. J Am Coll Cardiol 1994; 23:1356-1362.
     
     
149. Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy: A subset with distinctive left ventricular morphology and progressive clinical course late in life. J Am Coll Cardiol 1989; 13:36-45.
     
     
150. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985; 312:277-283.
     
     
151. Fay WP, Taliercio CP, Ilstrup DM, et al. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990; 16:821-826.
     
     
152. Haughland H Ohm OJ, Boman H, Thorsby E. Hypertrophic cardiomyopathy in three generations of a large Norwegian family. A clinical, echocardiographic and genetic study. Br. Heart J 1986; 55:168-175.
     
     
153. Olson LJ, Gertz MA, Edwards WD, et al. Senil cardiac amyloidosis with myocardial dysfunction: Diagnosis by endomyocardial biopsy and immunohistochemistry. N Engl J Med 1987; 317:738-742.
     
     
154. Pomerance A. Senil cardiac amyloidosis. Br Heart J 1965; 27:711-714.
     
     
155. Pitkanen P, Westermark P. Cornwell GG III. Senile systemic amyloidosis. Am J. Pathol 1984; 117:391-399.
     
     
156. Rubinow A Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981; 63:1285-1288.

Contenido